ABBVIE
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)
Phase 1
Not yet recruiting
- Conditions
- Dry Eye SyndromeSystemic Lupus Erythematosus
- Interventions
- First Posted Date
- 2025-05-18
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 36
- Registration Number
- NCT06977724
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
Phase 2
Not yet recruiting
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2025-05-15
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 180
- Registration Number
- NCT06972446
Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants With Advanced Parkinson Disease
Not yet recruiting
- Conditions
- Parkinson Disease
- First Posted Date
- 2025-05-11
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 270
- Registration Number
- NCT06965374
A Mass Balance Study of Oral [14C] ABBV-932 in Healthy Adult Male Participants
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 8
- Registration Number
- NCT06953934
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Phase 1
Not yet recruiting
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 130
- Registration Number
- NCT06953960
A Study to Assess the Bioavailability of Risankizumab Following Subcutaneous Administration With Prefilled Pen Relative to a Prefilled Syringe in Healthy Adult Participants
- First Posted Date
- 2025-04-27
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 60
- Registration Number
- NCT06946524
A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administration With On-Body Injector in Healthy Adult Participants
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 252
- Registration Number
- NCT06937619
- Locations
- 🇺🇸
Collaborative Neuroscience Research CNS /ID# 275212, Los Alamitos, California, United States
🇺🇸CenExel ACT- Anaheim Clinical Trials /ID# 274805, Anaheim, California, United States
🇺🇸Cpmi /Id# 274464, Miami, Florida, United States
Study on Practical ExperienceS of Treatment With Foslevodopa/foScaRbidopa in Advanced Parkinson's Disease
Recruiting
- Conditions
- Parkinson's Disease
- First Posted Date
- 2025-04-20
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 2000
- Registration Number
- NCT06937034
- Locations
- 🇸🇪
Karolinska University Hospital Solna /ID# 277116, Solna, Stockholms Lan, Sweden
🇳🇱Medisch Spectrum Twente /ID# 276695, Enschede, Overijssel, Netherlands
🇷🇴Universitatea De Medicină Și Farmacie Victor Babeș /ID# 276720, Timișoara, Timis, Romania
Study to Assess Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult German Participants at Initial Stages of Advanced Parkinson's Disease (EARLY-FOS)
Not yet recruiting
- Conditions
- Parkinson's Disease
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 125
- Registration Number
- NCT06916507
- Locations
- 🇩🇪
Parkinson-Klinik Ortenau GmbH&Co KG /ID# 274161, Wolfach, Baden-Wuerttemberg, Germany
A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Phase 2
Not yet recruiting
- Conditions
- Autosomal Dominant Polycystic Kidney Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-03-30
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 240
- Registration Number
- NCT06902558
© Copyright 2025. All Rights Reserved by MedPath